Emerging evidence indicates that the therapeutic benefits of tirzepatide extend beyond glycemic control, with clinically relevant effects on obesity, cardiovascular health, heart failure, kidney function, obstructive sleep apnea (OSA) and metabolic liver disease. Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist initially developed for the treatment of type 2 diabetes mellitus (T2DM). By activating both GIP and GLP-1 receptors, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying and reduces appetite. These complementary mechanisms produce substantial improvements in glycemic control and body weight. Increasing clinical evidence suggests that these metabolic effects may translate into broader cardiometabolic benefits, including improvements in obesity-related heart failure with preserved ejection fraction, renal function and OSA. 

Glycemic control and weight reduction 

Tirzepatide is among the most effective currently available pharmacological therapies for improving glycemic control and reducing body weight in individuals with T2DM and obesity. In the SURPASS-2 trial, tirzepatide produced greater reductions in glycated hemoglobin (HbA1c) than semaglutide 1 mg once weekly. Mean HbA1c reductions at 40 weeks were 2.01, 2.24 and 2.30 percentage points with tirzepatide 5, 10 and 15 mg, respectively, compared with 1.86 percentage points with semaglutide. Tirzepatide also resulted in greater weight loss than semaglutide.¹ In the SURMOUNT-1 trial, adults with obesity or overweight without diabetes experienced substantial weight loss over 72 weeks, with mean reductions of 15.0%, 19.5% and 20.9% with tirzepatide 5, 10 and 15 mg, respectively.² Longer-term follow-up over approximately three years demonstrated sustained weight reduction and a 94% lower risk of progression from prediabetes to T2DM compared with placebo.³ These findings highlight the potential role of tirzepatide not only in the management of T2DM and obesity but also in delaying or preventing the progression to diabetes among individuals at high risk. 

Cardiovascular benefits 

Cardiovascular disease represents a major cause of morbidity and mortality among individuals with T2DM and obesity. The SURPASS-CVOT trial compared tirzepatide with dulaglutide in patients with T2DM and established atherosclerotic cardiovascular disease. Tirzepatide was non-inferior to dulaglutide for the composite outcome of cardiovascular death, myocardial infarction or stroke.⁴  

Tirzepatide has also demonstrated benefits in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). In the SUMMIT trial, tirzepatide reduced the risk of a composite of cardiovascular death or worsening heart failure and improved health status and functional outcomes compared with placebo.⁵ Complementary real-world evidence from a population-based cohort of 52,971 adults with T2DM and established atherosclerotic cardiovascular disease showed that tirzepatide was associated with a lower one-year risk of MACE than sitagliptin (2.9% vs 4.4%; HR, 0.68; 95% CI, 0.58–0.80). Tirzepatide was also associated with lower risks of myocardial infarction and all-cause mortality, although no significant reduction in ischemic stroke was observed.⁶ These findings provide important evidence supporting the cardiovascular safety of tirzepatide and suggest that its overall cardiometabolic benefits extend beyond glycemic control. 

Renal benefits 

Renal protection is another emerging benefit of tirzepatide. In the SURPASS-4 trial, tirzepatide was associated with a slower decline in estimated glomerular filtration rate, greater reductions in urinary albumin-to-creatinine ratio and a lower risk of a composite kidney endpoint compared with insulin glargine.⁷ Pooled analyses of the SURPASS trials have also demonstrated reductions in albuminuria.⁸ Although these findings suggest potential renoprotective effects, dedicated renal outcome trials are required to determine whether tirzepatide reduces progression to advanced chronic kidney disease or kidney failure. 

Obstructive sleep apnea 

The effects of tirzepatide extend to obesity-associated respiratory disease. In the SURMOUNT-OSA trials, tirzepatide significantly reduced the severity of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity and improved several measures of sleep-disordered breathing compared with placebo.⁹ These findings highlight the potential of substantial pharmacological weight reduction to improve an important obesity-related comorbidity. Tirzepatide has subsequently gained regulatory recognition for the treatment of moderate-to-severe OSA in adults with obesity in the United States.¹⁰ 

Metabolic liver disease 

Tirzepatide is also being investigated for metabolic dysfunction-associated steatohepatitis (MASH). In the phase 2 SYNERGY-NASH trial, tirzepatide was more effective than placebo in achieving resolution of MASH without worsening of liver fibrosis after 52 weeks of treatment.¹¹ 

Safety and clinical considerations 

The principal adverse effects of tirzepatide are gastrointestinal, including nausea, diarrhea, vomiting and constipation. These effects are generally more prominent during dose escalation. Other important safety considerations include gallbladder disease, pancreatitis, dehydration-related kidney injury and hypersensitivity reactions. Tirzepatide carries a boxed warning regarding thyroid C-cell tumors based on animal studies and is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.⁹ 

Conclusion 

Tirzepatide has evolved from a glucose-lowering therapy into a broader metabolic treatment with benefits extending across several obesity- and diabetes-associated conditions. Strong evidence supports its effects on glycemic control and substantial weight reduction, while growing evidence indicates benefits in diabetes prevention, cardiovascular risk, obesity-related HFpEF, albuminuria, OSA and MASH. However, the strength of evidence varies among these outcomes, and some benefits remain supported primarily by secondary analyses or relatively short-duration trials. Further dedicated cardiovascular, renal, hepatic and long-term outcome studies will help define the full therapeutic potential of tirzepatide. Overall, its dual GIP/GLP-1 activity and pronounced effects on body weight position tirzepatide as an important component of the evolving treatment landscape for cardiometabolic disease. 

References 

1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503-515. 
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. 
3. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392:958-971. 
4. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393:2409-2420. 
5. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392:427-437. 
6. Krüger N, Schneeweiss S, Wang SV. Tirzepatide and the risk of atherosclerotic cardiovascular events: population-based cohort study. BMJ. 2026 Aug 5;394:e100011. 
7. Heerspink HJL, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial. Lancet Diabetes Endocrinol. 2022. 
8. Apperloo EM, et al. Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes. Diabetes Care. 2025.
9. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. 
10. US Food and Drug Administration. Tirzepatide prescribing information. Silver Spring (MD): US Food and Drug Administration; 2026. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf 
11. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391:299-310.